446 related articles for article (PubMed ID: 29867943)
1. Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways.
Lilienthal GM; Rahmöller J; Petry J; Bartsch YC; Leliavski A; Ehlers M
Front Immunol; 2018; 9():958. PubMed ID: 29867943
[TBL] [Abstract][Full Text] [Related]
2. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
[TBL] [Abstract][Full Text] [Related]
3. Impact of a three amino acid deletion in the CH2 domain of murine IgG1 on Fc-associated effector functions.
Baudino L; Nimmerjahn F; Shinohara Y; Furukawa J; Petry F; Verbeek JS; Nishimura S; Ravetch JV; Izui S
J Immunol; 2008 Sep; 181(6):4107-12. PubMed ID: 18768867
[TBL] [Abstract][Full Text] [Related]
4. Hyperacute rejection by anti-Gal IgG1, IgG2a, and IgG2b is dependent on complement and Fc-gamma receptors.
Ding JW; Zhou T; Zeng H; Ma L; Verbeek JS; Yin D; Shen J; Chong AS
J Immunol; 2008 Jan; 180(1):261-8. PubMed ID: 18097027
[TBL] [Abstract][Full Text] [Related]
5. Fc Galactosylation Promotes Hexamerization of Human IgG1, Leading to Enhanced Classical Complement Activation.
van Osch TLJ; Nouta J; Derksen NIL; van Mierlo G; van der Schoot CE; Wuhrer M; Rispens T; Vidarsson G
J Immunol; 2021 Sep; 207(6):1545-1554. PubMed ID: 34408013
[TBL] [Abstract][Full Text] [Related]
6. Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation.
Thommesen JE; Michaelsen TE; Løset GÅ; Sandlie I; Brekke OH
Mol Immunol; 2000 Nov; 37(16):995-1004. PubMed ID: 11395138
[TBL] [Abstract][Full Text] [Related]
7. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
8. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q.
Bindon CI; Hale G; Brüggemann M; Waldmann H
J Exp Med; 1988 Jul; 168(1):127-42. PubMed ID: 3260935
[TBL] [Abstract][Full Text] [Related]
9. IgG4 antibodies from patients with asymptomatic bancroftian filariasis inhibit the binding of IgG1 and IgG2 to C1q in a Fc-Fc-dependent mechanism.
Prodjinotho UF; Hoerauf A; Adjobimey T
Parasitol Res; 2019 Oct; 118(10):2957-2968. PubMed ID: 31485865
[TBL] [Abstract][Full Text] [Related]
10. Human IgG4: a structural perspective.
Davies AM; Sutton BJ
Immunol Rev; 2015 Nov; 268(1):139-59. PubMed ID: 26497518
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.
Tammen A; Derer S; Schwanbeck R; Rösner T; Kretschmer A; Beurskens FJ; Schuurman J; Parren PW; Valerius T
J Immunol; 2017 Feb; 198(4):1585-1594. PubMed ID: 28062698
[TBL] [Abstract][Full Text] [Related]
12. Structural difference in the complement activation site of human IgG1 and IgG3.
Michaelsen TE; Sandlie I; Bratlie DB; Sandin RH; Ihle O
Scand J Immunol; 2009 Dec; 70(6):553-64. PubMed ID: 19906198
[TBL] [Abstract][Full Text] [Related]
13. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.
Morgan A; Jones ND; Nesbitt AM; Chaplin L; Bodmer MW; Emtage JS
Immunology; 1995 Oct; 86(2):319-24. PubMed ID: 7490135
[TBL] [Abstract][Full Text] [Related]
14. Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model.
Li Q; Ujiie H; Shibaki A; Wang G; Moriuchi R; Qiao HJ; Morioka H; Shinkuma S; Natsuga K; Long HA; Nishie W; Shimizu H
J Immunol; 2010 Dec; 185(12):7746-55. PubMed ID: 21076071
[TBL] [Abstract][Full Text] [Related]
15. Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen.
Wang G; de Jong RN; van den Bremer ET; Beurskens FJ; Labrijn AF; Ugurlar D; Gros P; Schuurman J; Parren PW; Heck AJ
Mol Cell; 2016 Jul; 63(1):135-45. PubMed ID: 27320199
[TBL] [Abstract][Full Text] [Related]
16. Residue at position 331 in the IgG1 and IgG4 CH2 domains contributes to their differential ability to bind and activate complement.
Xu Y; Oomen R; Klein MH
J Biol Chem; 1994 Feb; 269(5):3469-74. PubMed ID: 8106388
[TBL] [Abstract][Full Text] [Related]
17. Glycine 236 in the Lower Hinge Region of Human IgG1 Differentiates FcγR from Complement Effector Function.
Brinkhaus M; Douwes RGJ; Bentlage AEH; Temming AR; de Taeye SW; Tammes Buirs M; Gerritsen J; Mok JY; Brasser G; Ligthart PC; van Esch WJE; Verheesen P; de Haard H; Rispens T; Vidarsson G
J Immunol; 2020 Dec; 205(12):3456-3467. PubMed ID: 33188070
[TBL] [Abstract][Full Text] [Related]
18. Engineering IgG1 Fc Domains That Activate the Complement System.
Lee CH; Delidakis G
Methods Mol Biol; 2022; 2421():187-200. PubMed ID: 34870820
[TBL] [Abstract][Full Text] [Related]
19. Binding of the human complement subcomponent C1q to hybrid mouse monoclonal antibodies.
Koolwijk P; Boot JH; Griep R; Bast BJ
Mol Immunol; 1991 Jun; 28(6):567-76. PubMed ID: 1861677
[TBL] [Abstract][Full Text] [Related]
20. Effects of weak/non-complement-binding HLA antibodies on C1q-binding.
Hönger G; Amico P; Arnold ML; Spriewald BM; Schaub S
HLA; 2017 Aug; 90(2):88-94. PubMed ID: 28585289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]